Vertex Pharmaceuticals has successfully acquired Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the company’s continued growth and diversification.
Vertex has acquired Crinetics for a total equity value of approximately US $10.0 billion, or approximately US $8.8 billion net of estimated cash acquired, subject to certain closing conditions. Following the receipt of necessary regulatory clearances the deal went through on 1 September 2026.
The Crinetics acquisition adds to Vertex’s innovation pipeline, accelerates revenue growth, and enhances the long-term earnings profile of the Company. The acquisition brings Palsonify (paltusotine) and atumelnant, in addition to several other pipeline programmes. Palsonify is the first and only once-daily oral therapy for acromegaly; it has been launched in the US, approved in the EU and is under review by other global regulatory bodies. Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist, is in phase 3 development for congenital adrenal hyperplasia (CAH) and in phase 2 development for Cushing’s syndrome. At peak, Palsonify and atumelnant have the potential to deliver more than $5 billion in combined annual revenue. The transaction is expected to become accretive to non-GAAP operating income in 2029.
Effective immediately, Charles Wagner, EVP and Chief Operating and Financial Officer, will expand his COO role to include leadership of the Crinetics integration. The Crinetics acquisition will establish rare endocrine diseases as the next pillar of growth, alongside the Company’s four existing areas of focus in cystic fibrosis, haematology, acute pain and renal.
Other senior position appointments were also announced.
